1. What Is New in HCM?

2. Program Goals

3. Disease Burden

4. Complications and Pathways of Disease Progression

5. Symptoms

6. Obstructive vs Nonobstructive HCM Assessment

7. Diagnostic Challenges

8. Approved Disease-Specific Therapy To Date: Only Propranolol

9. Symptomatic Nonobstructive HCM ACCF/AHA Treatment Algorithm

10. Symptomatic Obstructive HCM ACCF/AHA Treatment Algorithm

11. Evaluate for an Implantable Defibrillator

12. Investigational Therapies

13. Mavacamten (Formerly MYK-461)

14. Baseline Characteristics in PIONEER (Part A)

15. Primary Endpoint: Rapid Reduction in Post-Exercise LVOT Gradient

16. Significant Improvement in Peak VO2 by Week 12

17. Improvement in NYHA Functional Class

18. Research

19. Abbreviations